FGP
PHAT icon

Freestone Grove Partners’s Phathom Pharmaceuticals PHAT Stock Holding History

Freestone Grove Partners’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-84,573
Closed -$940K – 1254
2026
Q1 		$940K Buy
+84,573
New +$1.07M 0.01% 496

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Freestone Grove Partners's PHAT Position: Q2 2026 in Review

Freestone Grove Partners sold out of Phathom Pharmaceuticals (PHAT) in Q2 2026, closing a stake of 84,573 shares — an estimated $940K sold.

Freestone Grove Partners first reported a position in PHAT in Q1 2026 and held it in 1 quarter. The position peaked at $940K in Q1 2026. 162 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Freestone Grove Partners reported no remaining Phathom Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Freestone Grove Partners sold 84,573 Phathom Pharmaceuticals shares in Q2 2026, an estimated $940K.
  • Freestone Grove Partners first reported a position in Phathom Pharmaceuticals in Q1 2026 and held it in 1 quarter.
  • Freestone Grove Partners's Phathom Pharmaceuticals position peaked at $940K in Q1 2026.
  • 162 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.